Why Is Tiziana Life Sciences Stock Gaining Thursday?

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) announced a memorandum of understanding to evaluate a combination therapy for relapsing-remitting multiple sclerosis, leading to a stock increase of over 21%, reaching $0.93. The collaboration involves the King Abdullah International Medical Research Center and aims to address poor responses to existing anti-CD20 therapies. Tiziana's Phase 2 trial results for non-active secondary progressive multiple sclerosis are expected in October, with positive outcomes reported from patients receiving foralumab through an Expanded Access Program.